Two New Antibodies Found to Cripple HIV-Achilles — Cost, Top Hospitals & Success Rates | MyMedicPlus

Broadly neutralising antibodies (bNAbs) against HIV represent one of the most significant areas of active research in the quest for an HIV cure or functional cure. Unlike standard antiretroviral therapy (ART), which suppresses viral replication but does not eliminate latently infected cells, broadly neutralising antibodies target conserved sites on the HIV envelope protein that are essential for the virus to enter CD4+ T cells. Because these sites are functionally constrained — meaning HIV cannot easily mutate them without losing its ability to infect cells — they represent an 'Achilles heel' of the virus that remains consistently vulnerable across diverse HIV strains and clades.

The identification of potent bNAbs targeting the CD4 binding site, the V3 glycan supersite, and the membrane-proximal external region (MPER) of HIV gp120 and gp41 envelope proteins has accelerated over the past decade, enabled by technological advances in B-cell isolation from HIV-infected individuals who develop natural broadly neutralising responses (so-called 'elite controllers' or 'elite neutralisers'). These rare individuals — representing approximately 1% of chronically infected people — mount antibody responses that neutralise 50-90% of diverse HIV strains globally.

Two categories of recently identified bNAbs — targeting the CD4 binding site (such as VRC01, N6LS, and 3BNC117) and the V3-glycan supersite (such as PGT121, 10-1074) — have entered clinical trials for HIV prevention and therapeutic use. Early-phase human trials demonstrate that infusion of these antibodies produces measurable viral load suppression and delays viral rebound after interruption of standard ART, validating the concept of antibody-mediated HIV control.

Broadly neutralising antibodies are being developed for three distinct clinical applications in HIV management. For HIV prevention (pre-exposure prophylaxis), bNAbs represent a promising long-acting alternative to daily oral PrEP (tenofovir/emtricitabine) — a single subcutaneous or intravenous infusion of a long-acting bNAb may provide months of HIV protection. The HVTN 703/HPTN 085 and HVTN 704/HPTN 081 trials evaluating VRC01 demonstrated partial protection against HIV acquisition in diverse populations, with the first clinical evidence of bNAb-mediated prevention in humans.

For HIV treatment, bNAbs are being studied in combination with ART in analytical treatment interruption (ATI) protocols — a research approach in which ART is safely paused under careful monitoring to evaluate whether bNAbs can maintain viral suppression and delay or prevent viral rebound. The TITAN trial and similar studies have demonstrated that combinations of two or more bNAbs with complementary epitope specificities produce synergistic viral suppression significantly superior to single-agent bNAb treatment. Additionally, bNAbs are being studied as components of 'shock and kill' HIV cure strategies — activating latently infected cells with latency-reversing agents while bNAbs neutralise released virus and direct immune-mediated killing of reservoir cells. These approaches hold theoretical potential for reducing the HIV reservoir, a prerequisite for functional or sterilising cure.

Clinical trials evaluating broadly neutralising antibodies for HIV are recruiting specific participant profiles. For prevention trials, high-risk HIV-negative adults at elevated risk of HIV acquisition through sexual exposure are enrolled. For therapeutic trials, HIV-positive adults on stable ART with undetectable viral loads who are interested in analytical treatment interruption research protocols are eligible. Participants must demonstrate that the circulating HIV strains in their body are sensitive to the specific bNAbs being studied — this is assessed through virological phenotyping before enrolment.

bNAb therapy is not yet approved for routine clinical use outside of clinical trials. Individuals interested in participating should seek enrolment through HIV clinical trial registries (ClinicalTrials.gov) or specialist HIV research centres. Post-marketing use of bNAbs will likely be indicated for HIV-positive individuals who harbour multidrug-resistant HIV strains unresponsive to standard ART, for long-acting HIV prevention in populations with barriers to daily oral PrEP adherence, and potentially as part of combination strategies aimed at HIV functional cure in individuals achieving specific immunological or virological criteria.

Single-agent bNAb infusion has demonstrated proof-of-concept viral suppression in early clinical trials but is limited by the emergence of bNAb-resistant viral variants within weeks to months. Combination bNAb therapy using two or three antibodies targeting distinct, non-overlapping HIV envelope epitopes significantly reduces the probability of resistance emergence — analogous to the triple-drug ART regimens that solved the problem of single-drug resistance in the 1990s. The combination of VRC07-523LS (CD4 binding site) + 10-1074 (V3 glycan) or 3BNC117 + 10-1074 has demonstrated promising results in published Phase I/II clinical trials.

Long-acting formulations of bNAbs using LS (leucine serine) modifications to the antibody Fc region extend half-life from 3-4 weeks to 4-6 weeks, enabling monthly or bi-monthly dosing — comparable to the long-acting injectable ART regimens (cabotegravir, rilpivirine) that have transformed HIV treatment adherence. Subcutaneous self-injection formulations are in development to enable outpatient administration. Bispecific antibodies — engineered molecules that simultaneously bind two different HIV epitopes — combine two bNAb specificities into a single molecule, potentially simplifying combination regimens. Antibody-drug conjugates that direct cytotoxic payloads to latently infected HIV reservoir cells express the bNAb's targeting specificity with the ability to kill infected cells rather than merely neutralise free virus. These broadly neutralising antibodies represent a paradigm shift toward passive immunotherapy as an HIV treatment and prevention strategy, with current Phase II/III trials evaluating long-acting injectable formulations that may provide months of protection per dose, potentially transforming HIV management beyond daily antiretroviral pill regimens.

The primary benefit of broadly neutralising antibodies over current ART is their potential to address aspects of HIV control that small-molecule drugs cannot achieve. As passive immunotherapy, bNAbs harness the immune system's own mechanisms — Fc-mediated antibody-dependent cellular cytotoxicity (ADCC) and complement activation — to directly kill HIV-infected cells, not just prevent viral spread. This potentially provides both antiviral and immunomodulatory benefits simultaneously.

Published Phase I/II trials of VRC01 demonstrate average viral load reductions of 1.5-2.0 log10 copies/mL after a single infusion in HIV-positive individuals off ART, with duration of response correlating with antibody half-life. The combination of 3BNC117 + 10-1074 produced viral suppression for a median of 21 weeks in a small Phase II trial — a duration that, if sustained with long-acting formulations, would represent a transformative advance. For prevention, the HVTN 703/704 trial demonstrated 75% protection against VRC01-sensitive HIV strains with the current formulation — and estimates suggest up to 97% protection against sensitive strains at optimised dosing. These results establish bNAbs as a viable prevention modality for populations unable to consistently adhere to daily oral PrEP.

Broadly neutralising antibodies have demonstrated an excellent safety profile in Phase I and II clinical trials. Infusion reactions (mild fever, chills, headache, nausea) occur in a minority of participants, typically manageable with antihistamines and paracetamol. Serious infusion reactions (anaphylaxis) are rare but have been reported and require standard anaphylaxis management. Injection site reactions with subcutaneous formulations include temporary pain and induration.

The most significant biological risk is the emergence of bNAb-resistant HIV variants. While bNAbs target conserved regions less susceptible to mutation than the targets of standard ART, resistance mutations have been documented in clinical trial participants treated with single-agent bNAbs — particularly within the V3 glycan loop and CD4 binding site regions. Combination bNAb therapy dramatically reduces this risk. In participants who develop viral rebound on bNAbs after ART interruption, the bNAb-resistant variants are typically sensitive to re-introduction of standard ART. There is no evidence from current trials that bNAb use compromises subsequent ART efficacy. Long-term immunogenicity — the development of host immune responses against the antibody molecules themselves — is being monitored in ongoing trials.

In clinical trial settings, participants receiving bNAb infusions are monitored for 1-2 hours post-infusion for infusion reactions, then followed with intensive virological and immunological monitoring including HIV viral load measurement every 2-4 weeks. Participants in analytical treatment interruption protocols have predefined stopping rules (typically restart of ART when viral load exceeds 1,000 copies/mL) to prevent immunological harm from prolonged uncontrolled viraemia.

For prevention trial participants, safety monitoring visits occur monthly, including HIV testing to detect breakthrough infections, and bNAb plasma concentrations are measured to document pharmacokinetics. Future clinical practice (post-approval) for therapeutic bNAbs is anticipated to involve infusions or subcutaneous injections every 4-8 weeks, with viral load monitoring at 1-3 monthly intervals, consistent with the monitoring frequency for standard ART. CD4 count monitoring will continue as a key marker of immune function. Combination bNAb therapy in a long-acting injectable format may ultimately offer a viable alternative to daily oral ART for selected patients.

Broadly neutralising antibodies are not yet commercially available and therefore have no established market price. Manufacturing monoclonal antibodies is substantially more expensive than producing small-molecule antiretrovirals — early estimates suggest that bNAb treatment could cost USD 10,000-30,000 per patient per year at current manufacturing costs if commercialised at US market prices for other monoclonal antibodies. This would represent a significant cost barrier to global access, particularly in the low- and middle-income countries where 70% of HIV-infected individuals live.

Medédicins Sans Frontières and civil society organisations have advocated strongly for technology transfer and tiered pricing mechanisms to ensure that future bNAb products are accessible in high-burden countries at affordable prices. Research funders including the Gates Foundation and NIH NIAID, as well as international partnerships such as the Coalition for Epidemic Preparedness Innovations (CEPI), are investing in manufacturing scale-up and cost-reduction strategies. If approved, bNAbs for prevention may be available as a public health intervention in low-income countries through programmes similar to PEPFAR or the Global Fund, potentially at negotiated prices of USD 100-500 per year analogous to long-acting injectable cabotegravir PrEP cost structures being negotiated for Sub-Saharan Africa.

Current standard of care for HIV treatment is antiretroviral therapy (ART) — combinations of two to three drugs from the nucleoside/nucleotide reverse transcriptase inhibitor (NRTI), integrase strand transfer inhibitor (INSTI), and/or non-nucleoside reverse transcriptase inhibitor (NNRTI) classes. Modern first-line regimens including bictegravir/tenofovir alafenamide/emtricitabine (Biktarvy) achieve and maintain viral suppression below the level of detection in over 90% of treatment-naive patients with once-daily dosing. Long-acting injectable regimens (cabotegravir + rilpivirine every 2 months) provide an ART alternative for patients with adherence challenges to daily oral medications.

For HIV prevention, daily oral PrEP with tenofovir disoproxil fumarate/emtricitabine (Truvada) reduces HIV acquisition risk by over 99% with consistent use and is widely available. Long-acting injectable cabotegravir (HPTN 083/084) provides superior adherence-independent protection at two-monthly injections. Male circumcision reduces HIV acquisition risk in heterosexual men by approximately 60%. Behavioural prevention — consistent condom use, regular HIV testing, and treatment of co-existing sexually transmitted infections — remains fundamental. bNAbs represent a next-generation approach that complements rather than immediately replaces these established prevention and treatment options.